ReviewCell proliferation2025
Extrachromosomal Circular DNA in Cancer: Mechanisms and Clinical Applications.
Review in Cell proliferation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Extrachromosomal DNA Amplification as a Prognostic Factor for Cancer.Journal of personalized medicine · 2026Review
- Circular RNAs: Key Regulators of Tumor Metabolic Reprogramming and Clinical Translation.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extrachromosomal circular DNA (eccDNA) has emerged as a critical area of cancer research due to its ubiquitous presence in tumour cells and significant role in tumorigenesis, progression and drug resistance. Recent studies demonstrate that eccDNA promotes cancer progression by influencing genomic instability, amplifying oncogenes, regulating gene expression and enhancing tumour cell adaptability to adverse conditions. While the precise mechanisms underlying eccDNA formation and its biological functions remain unclear, its potential applications in cancer diagnosis, prognosis and targeted therapy are gaining increasing recognition. This review summarises the latest advancements in eccDNA research, highlighting its potential as both a biomarker and a therapeutic target. Additionally, it emphasises the translational potential of eccDNA in clinical diagnostics and personalised treatment strategies, offering new perspectives for future cancer research and innovative therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.